Suppr超能文献

他汀类药物对冠心病风险的影响:随机对照试验的荟萃分析

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

作者信息

LaRosa J C, He J, Vupputuri S

机构信息

Office of the President, State University of New York Health Science Center at Brooklyn, 11203, USA.

出版信息

JAMA. 1999;282(24):2340-6. doi: 10.1001/jama.282.24.2340.

Abstract

CONTEXT

Lowering low-density lipoprotein cholesterol (LDL-C) is known to reduce risk of recurrent coronary heart disease in middle-aged men. However, this effect has been uncertain in elderly people and women.

OBJECTIVE

To estimate the risk reduction of coronary heart disease and total mortality associated with statin drug treatment, particularly in elderly individuals and women.

DATA SOURCES

Trials published in English-language journals were retrieved by searching MEDLINE (1966-December 1998), bibliographies, and authors' reference files.

STUDY SELECTION

Studies in which participants were randomized to statin or control treatment for at least 4 years and clinical disease or death was the primary outcome were included in the meta-analysis (5 of 182 initially identified).

DATA EXTRACTION

Information on sample size, study drug duration, type and dosage of statin drug, participant characteristics at baseline, reduction in lipids during intervention, and outcomes was abstracted independently by 2 authors (J.H. and S.V.) using a standardized protocol. Disagreements were resolved by consensus.

DATA SYNTHESIS

Data from the 5 trials, with 30 817 participants, were included in this meta-analysis. The mean duration of treatment was 5.4 years. Stati n drug treatment was associated with a20% reduction in total cholesterol, 28% reduction in LDL-C, 13% reduction in triglycerides, and 5% increase in high-density lipoprotein cholesterol. Overall, statin drug treatment reduced risk 31 % in major coronary events (95% confidence interval [CI], 26%-36%) and 21 % in all-cause mortality (95% CI, 14%-28%). The risk reduction in major coronary events was similar between women (29%; 95% Cl, 13 %-42 %) and men (31 %; 95% CI, 26%-35%), and between persons aged at least 65 years (32%; 95% CI, 23%-39%) and persons younger than 65 years (31 %; 95% CI, 24%-36%).

CONCLUSIONS

Our meta-analysis indicates that reduction in LDL-C associated with statin drug treatment decreases the risk of coronary heart disease and all-cause mortality. The risk reduction was similar for men and women and for elderly and middle-aged persons.

摘要

背景

降低低密度脂蛋白胆固醇(LDL-C)可降低中年男性复发性冠心病的风险。然而,这种效果在老年人和女性中尚不确定。

目的

评估他汀类药物治疗相关的冠心病风险降低及全因死亡率,尤其是在老年人和女性中。

数据来源

通过检索MEDLINE(1966年至1998年12月)、参考文献及作者的参考文献档案,获取发表于英文期刊的试验。

研究选择

将参与者随机分配至他汀类药物或对照治疗至少4年且以临床疾病或死亡为主要结局的研究纳入荟萃分析(最初识别的182项研究中的5项)。

数据提取

2位作者(J.H.和S.V.)使用标准化方案独立提取关于样本量、研究药物持续时间、他汀类药物类型和剂量、基线时参与者特征、干预期间血脂降低情况及结局的信息。分歧通过协商解决。

数据合成

来自5项试验、共30817名参与者的数据纳入本荟萃分析。平均治疗持续时间为5.4年。他汀类药物治疗使总胆固醇降低20%,LDL-C降低28%,甘油三酯降低13%,高密度脂蛋白胆固醇升高5%。总体而言,他汀类药物治疗使主要冠脉事件风险降低31%(95%置信区间[CI],26% - 36%),全因死亡率降低21%(95%CI,14% - 28%)。女性(29%;95%CI,13% - 42%)和男性(31%;95%CI,26% - 35%)之间,以及年龄至少65岁者(32%;95%CI,23% - 39%)和年龄小于65岁者(31%;95%CI)之间,主要冠脉事件风险降低相似。

结论

我们的荟萃分析表明,他汀类药物治疗相关的LDL-C降低可降低冠心病风险和全因死亡率。男性和女性、老年人和中年人风险降低相似。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验